Hoth Therapeutics Inc. announced on 20 May that it is licensing technology and related intellectual property developed at Virginia Commonwealth University that it will use to develop a potential peptide therapy to prevent replication of the COVID-19. No financial terms were disclosed.
Research led by VCU professor Michael Peters developed a novel peptide that may inhibit binding of the virus’ spike protein to cell surface receptor angiotensin converting enzyme 2 (ACE2), which is dispersed widely throughout the body, the partners said
